UK Registered Veterinary Retailer
Carprieve

  • 20mg Flavour » Priced per Tablet £0.49
  • 20mg Original (small white) » Priced per Tablet £0.40
  • 50mg Flavour » Priced per Tablet £0.79
  • 50mg Original (small white) » Priced per Tablet £0.59
  • 100mg Flavour » Priced per Tablet £1.30
  • 100mg Original (small white) » Priced per Tablet £1.09

Selection of 6 products from

£0.40 to £1.30

Description

Carprieve is used to reduce pain and inflammation. It is effective for chronic conditions such as degenerative joint disease (osteoarthritis) as well as injuries to the musculo-skeletal system. It can also be used as an aid in post-operative recovery. In common with other NSAIDs, Carprieve should not be used in dehydrated or debilitated dogs, and medication should be paused or terminated if vomiting or diarrhoea occur.

Carprieve is available in unflavoured (small, white) tablets, or in larger flavoured and palatable, chewable tablets

N.B. - Carprieve was previously called Norocarp.

Contra-indications, warnings, etc

The use of Norocarp Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.
Do not exceed the stated dose.
Do not administer NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.
In the absence of any specific studies in pregnant target bitches, such use is not indicated.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

20mg Original (small white) » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. Name of the veterinary medicinal product

    Carprieve Tablets 20mg

  2. Qualitative and quantitative composition

Active Substance:

Each tablet contains:

Carprofen    20 mg

Excipients:

For a full list of excipients, see section 6.1

  1. Pharmaceutical form

    Tablet A white/off white circular tablet of diameter 8 mm, 20 embossed on one side and a single break line on the other side.

  2. Clinical Particulars

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.  

Carprieve Tablets can also be used in the management of post-operative pain.

4.3 Contraindications

The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.
Do not exceed the stated dose.
Do not administer NSAIDs concurrently or within 24 hours of each other.  Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
In the absence of any specific studies in pregnant bitches such use is not indicated.  

4.4 Special Warnings for each target species

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk.  If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.  

4.5 Special precautions for use

Special precautions for use in animals

None.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

None.

4.6 Adverse reactions (frequency and seriousness)

None.

4.7 Use during pregnancy, lactation or lay

In the absence of any specific studies in pregnant bitches such use is not indicated.  

4.8 Interaction with other medicinal products and other forms of interaction

Do not administer NSAIDs concurrently or within 24 hours of each other.  Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

4.9 Amounts to be administered and administration route

For oral administration.
An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in 2 equally divided doses.  The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response.
Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets.  

Overdose (symptoms, emergency procedures, antidotes), if necessary

Not applicable.

Withdrawal period

Not applicable
  1. pharmacological properties

Pharmacotherapeutic group: Non-steroidal anti-inflammatory drug

ATC Vet Code: QM01AE91

Pharmacodynamic properties

Carprofen, ()-6-chloro--methylcarbazole-2-acetic acid, is a non-steroidal anti-inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C2 of the propionic moiety and therefore, exists in 2 sterioisomeric forms, the (+)-S and (-)-R enantiomers.

5.2 Pharmacokinetic properties

Following oral administration of 4mg carprofen/kg to dogs, peak plasma concentrations (mean Cmax = 28.51 g/ml) were achieved in 4 hours.

Absorption of carprofen is rapid and complete in the dog.  The volume of distribution is small with the highest drug concentrations occurring in plasma.  Ratios of tissue to plasma concentration are less than one, which is consistent with a high level of binding of carprofen to plasma proteins.
  1. Pharmaceutical particulars

6.1 List of excipients Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Poly-vinyl pyrrolidone K 30 Sodium laurilsulfate Magnesium stearate Purified water

Incompatibilities

None.

Shelf life

Tubs: 36 months Blister strips: 24 months

Special precautions for storage

Do not store above 25ºC. Store in a dry place. Protect from light.

Nature and composition of immediate packaging

Carprieve Tablets are supplied in:

Polypropylene Snap Secure Tubs, containing 100 tablets, sealed with a white Polyethylene Snap Secure Cap.

Alu/Alu blister strips of 2 x 5 tablets

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements.

  1. MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP Northern Ireland

  1. MARKETING AUTHORISATION NUMBER(S)

    ManA: 2000 Vm: 02000/4220

  2. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

    5th September 2003/ 5th September 2008

DATE OF REVISION OF THE TEXT

January 2009

50mg Original (small white) » Priced per Tablet

Carprieve 50 mg Tablets for Dogs

Qualitative and quantitative composition

Each tablet contains: Active Substance: Carprofen50 mgExcipients:

Active Substance:

Carprofen

50 mg

Excipients:

For a full list of excipients, see section Pharmaceutical Particulars

Pharmaceutical form

Tablet.

A white/off white circular tablet of diameter 8 mm, 50 embossed on one side and a single break line on the other side.

Clinical particulars

Target species

Dogs

Indications for use, specifying the target species

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.

Carprieve Tablets can also be used in the management of post-operative pain.

Contraindications

The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.

Do not exceed the stated dose.

Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Special Warnings for each target species

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Special precautions for use

Special precautions for use in animals

None.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

None.

Adverse reactions (frequency and seriousness)

None.

Use during pregnancy, lactation or lay

In the absence of any specific studies in pregnant bitches such use is not indicated.

Interaction with other medicinal products and other forms of interaction

Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

Amounts to be administered and administration route

For oral administration.

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in 2 equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets.

Overdose (symptoms, emergency procedures, antidotes), if necessary

There is no specific antidote for carprofen overdosage but general supportive therapy as applied to clinical overdosage with NSAIDs should be applied.

Withdrawal period

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: Non-steroidal anti-inflammatory drug

ATC Vet Code: QM01AE91

Pharmacodynamic properties

Carprofen, (±)-6-chloro-α-methylcarbazole-2-acetic acid, is a non-steroidal anti-inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C2 of the propionic moiety and therefore, exists in 2 sterioisomeric forms, the (+)-S and (-)-R enantiomers.

Pharmacokinetic properties

Following oral administration of 4mg carprofen/kg to dogs, peak plasma concentrations (mean Cmax = 28.51 μg/ml) were achieved in 4 hours.

Absorption of carprofen is rapid and complete in the dog. The volume of distribution is small with the highest drug concentrations occurring in plasma. Ratios of tissue to plasma concentration are less than one, which is consistent with a high level of binding of carprofen to plasma proteins.

Pharmaceutical particulars

List of excipients

Microcrystalline cellulose

Lactose monohydrate

Croscarmellose sodium

Poly-vinyl pyrrolidone K 30

Sodium laurilsulfate

Magnesium stearate

Purified water

Incompatibilities

None.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale:

Tubs: 36 months

Blister strips: 24 months

Special precautions for storage

Do not store above 25°C.

Store in a dry place.

Protect from light.

Nature and composition of immediate packaging

Carprieve Tablets are supplied in:

Polypropylene Snap Secure Tubs, containing 100 or 500 tablets, sealed with a white Polyethylene Snap Secure Cap.

Alu/Alu blister strips of 2 x 5 tablets.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements.

Marketing Authorisation Holder (if different from distributor)

Norbrook Laboratories Limited

Station Works

Newry

Co. Down

BT35 6JP

Northern Ireland

Marketing Authorisation Number

Vm 02000/4221

Date of the first authorisation or date of renewal

5th September 2003/ 5th September 2008

Date of revision of the text

January 2009

Any other information

Nil.

Legal category

100mg Original (small white) » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

    Carprieve 100mg Tablets for Dogs

  2. QUALITATIVE AND QUANTITATIVE COMPOSITION

    Each tablet contains:

    Active Ingredients: Carprofen 100 mg

    Excipients: Tartrazine (E102) 1.2 mg

    For the full list of excipients, see section 6.1

  3. PHARMACEUTICAL FORM

    Tablet

A yellow circular tablet of 8 mm diameter, 100 embossed on one side and a single breakline on the other side.

The tablets can be divided into halves.

  1. CLINICAL PARTICULARS

4.1 Target Species

Dogs

4.2 Indications for use, specifying the target species

In the dog:
Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain.

4.3 Contraindications

    Do not use in cats.
    Do not use in pregnant or lactating bitches.
    Do not use in puppies less than 4 months of age.
Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.”

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

4.4 Special warnings for each target species

Refer to Sections 4.3 and 4.5. 

4.5 Special precautions for use

Special precautions for use in animals

Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Refer to section 4.8

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

4.6 Adverse reactions (frequency and seriousness)

Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.

As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

4.7 Use during pregnancy, lactation or lay

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose.  The safety of the veterinary medicinal product has not been established during pregnancy and lactation.  Do not use in pregnant or lactating bitches.  

4.8 Interaction with other medicinal products and other forms of interaction

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

    Concurrent administration of potential nephrotoxic drugs should be avoided.

4.9 Amounts to be administered and administration route

    For oral administration.
    4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses.  The daily dose may be reduced, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision. Do not exceed the stated dose. To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprofen Tablets at 4 mg/kg/day for up to 5 days. Return any halved tablets to the original pack and use at the next administration. Any halved tablets remaining after the last administration of the product must be discarded

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Do not exceed the stated dose. There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

4.11 Withdrawal Period(s)

Not applicable
  1. PHARMACOLOGICAL OR IMMUNOLOGICAL PROPERTIES

    Pharmacotherapeutic group: Non-steroidal anti-inflammatory drug

    ATC Vet Code : QM01AE91

5.1 Pharmacodynamic properties

Carprofen, ()-6-chloro--methylcarbazole-2-acetic acid, is a non-steroidal anti-inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C2 of the propionic moiety and therefore, exists in 2 sterioisomeric forms, the (+)-S and (-)-R enantiomers.
Carprofen possess anti-inflammatory, anaglesic and anti-pyretic activity. Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.

5.2 Pharmacokinetic properties

Absorption is rapid with >90% absorption after oral administration. The volume of distribution is small and carprofen is highly bound to plasma proteins. Biotransformation of carprofen occurs in the liver to form the ester glucuronide and two 1-O-acyl-β-D-glucuronide diastereoisomers. These are secreted in the biliary tract and excreted in the faeces. The Cmax is 28.51 µg/ml and the AUC is 237.33 µg/ml.hour.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tartrazine (E102) Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Povidone K 30 Sodium laurilsulphate Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

6.4 Special precautions for storage

Do not store above 25ºC.

Store in a dry place. Protect from light.

6.5 Nature and composition of immediate packaging

Carprieve 100mg Tablets are supplied in either:

Polypropylene Snap Secure Tubs containing 14, 30 or 100 tablets, sealed with a white low density Polyethylene Snap Secure Cap, or Aluminium-Aluminium blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

    Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down, BT35 6JP Northern Ireland

  2. MARKETING AUTHORISATION NUMBER

    Vm 02000/4283

  3. DATE OF FIRST AUTHORISATION

    21 July 2009

  4. DATE OF REVISION OF TEXT

    June 2014

Approved: 17/06/2014

100mg Flavour » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. Name of the veterinary medicinal product

    Carprieve 100 mg Flavoured Tablets for Dogs (UK, AT, BG, CY, CZ, EE, IE, LV, LT, RO, SK, SL) Norocarp 100mg Flavoured Tablets for Dogs (BE, EL, HU, IT, LU, NL. PT, ES) Norodyl Flavour 100mg Tablets for Dogs (DK) Carprieve 100 mg Chewable Tablets for Dogs (FI) Carprieve F 100mg Tablets for Dogs (FR) Carprieve 100mg Flavoured Tablets for Dogs (DE) Scanodyl 100mg Flavoured Tablets for Dogs (PL) Norocarp vet 100 mg Chewable Tablets for Dogs (SE)

  2. Qualitative and quantitative composition

    Each tablet contains:
    

    Active Substance: Carprofen 100mg

Excipients:

For the full list of excipients see section 6.1
  1. Pharmaceutical form

    Tablet. Light brown, round, flat, bevel edged tablet The tablets can be divided into equal parts.

  2. Clinical Particulars

4.1 Target species:

Dogs

4.2 Indications for use, specifying the target species:

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease in the dog.

The tablets also can be used in the management of post operative pain.

Contraindications:

Do not exceed the stated dose.

Do not use in cats.  

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.

Do not use in puppies less than 4 months.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Refer to section 4.7 and 4.8

4.4 Special Warnings for each target species:

See sections 4.3 and 4.5.

 Special precautions for use:

Special precautions for use in animals:

Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion seek medical advice and show the package leaflet or the label to the physician. Wash hands after handling product.

4.6 Adverse reactions (frequency and seriousness):

Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

As with other NSAIDs there is a risk of rare renal or idosyncratic hepatic adverse events.

4.7 Use during pregnancy, lactation or lay:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose.  The safety of the veterinary medicinal product has not been established during pregnancy and lactation.  Do not use in pregnant or lactating bitches.  For breeding animals, do not use during reproduction period.

Interaction with other medicinal products and other forms of interaction:

Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects.  Do not use this veterinary medicinal product concurrently with or within 24 hours of other NSAIDs or concurrently with glucocorticoids.  

Concurrent administration of potentially nephrotoxic drugs should be avoided. Refer also to section 4.5.

Do not administer concurrently with anticoagulants.

Amounts to be administered and administration route:

For oral administration. The tablets are palatable and willingly consumed by most dogs when offered. 2 to 4 mg carprofen per kg bodyweight per day. An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose. Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4mg/kg/day for up to 5 days. Do not exceed the stated dose.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary:

No signs of toxicity were observed when dogs were administered the product at levels up to 6 mg/kg twice daily for 8 days (3 times the maximum recommended dose rate of 4 mg/kg/day) and 6 mg/kg once daily for a further 7 days (1.5 times the maximum recommended dose rate of 4 mg/kg/day). There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs, should be applied.

Severe adverse reactions may occur if large quantities are ingested. If you suspect that your dog has consumed tablets above the labelled dose, contact your veterinarian.

4.11 Withdrawal period:

Not applicable

  1. pharmacological properties

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids, proprionic acid derivatives, carprofen. ATC Vet Code: QM01AE91

5.1 Pharmacodynamic properties:

Carprofen is a member of the 2 –arylpropionic acid group of non steroidal anti-inflammatory drugs (NSAIDs) and possesses anti-inflammatory, analgesic and antipyretic activity.

Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. At therapeutic doses in the dog inhibition of the products of cyclo-oxygenase (prostaglandins and thromboxanes) or lipoxygenase (leukotrienes) has been absent or slight. The precise mode of action of carprofen is not clear.

5.2 Pharmacokinetic Particulars

After a single oral administration of 4 mg of carprofen per kg of bodyweight in dogs, the time to obtain a maximum plasmatic concentration of 31 g/ml is 2.5 hours.  The oral bioavailability is more than 90% of the total dose.  Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low.  Carprofen is excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate.  Carprofen undergoes an enantioselective enterohepatic cycle in dogs, with only the S(+) enantiomer being significantly recycled.  The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen.  The biliary clearance of S(+) carprofen seems to be subject to stereoselectively too as it is about three times higher than that of R(-) carprofen.    

Carprofen is mainly excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate, and 8-15% via urine.
  1. Pharmaceutical particulars

6.1 List of excipients:

Lactose Monohydrate
Sodium Laurilsulfate
Spray dried Pig liver powder EHT
Sucrose
Yeast extract (dried)
Ground Wheatgerm Starch Pregelatinised
Povidone K30
Microcrystalline Cellulose Guar Gum Magnesium Stearate

6.2 Incompatibilities:

Not applicable

6.3 Shelf life:

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.

Shelf-life after first opening the immediate packaging: 24 hours. Any divided tablet portions remaining after 24 hours should be discarded.

6.4 Special precautions for storage:

Store in a dry place. Protect from light. Do not store above 25ºC Divided tablets should be stored in the blister pack.

6.5 Nature and composition of immediate packaging:

Aluminium-Aluminium packs of 5 tablets per strip in cartons containing 20, 25, 100, or 200 tablets. Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

    Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP Northern Ireland

  2. MARKETING AUTHORISATION NUMBER

    Vm 02000/4305

  3. DATE OF FIRST AUTHORISATION

    14 March 2011

  4. DATE OF REVISION OF THE TEXT

    May 2016

    Approved: 20 May 2016

20mg Flavour » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. Name of the veterinary medicinal product

    Carprieve 20 mg Flavoured Tablets for Dogs (UK, AT, BG, CY, CZ, EE, IE, LV, LT, RO, SK, SL) Norocarp 20mg Flavoured Tablets for Dogs (BE, EL, HU, IT, LU, NL. PT, ES) Norodyl Flavour 20mg Tablets for Dogs (DK) Carprieve 20 mg Chewable Tablets for Dogs (FI) Carprieve F 20mg Tablets for Dogs (FR) Carprieve 20mg Flavoured Tablets for Dogs (DE) Scanodyl 20mg Flavoured Tablets for Dogs (PL) Norocarp vet 20 mg Chewable Tablets for Dogs (SE)

  2. Qualitative and quantitative composition

    Each tablet contains:
    

Active Substance: Carprofen 20mg

Excipients: For the full list of excipients see section 6.1

  1. Pharmaceutical form

    Tablet. Light brown, round, flat, bevel edged tablet The tablets can be divided into equal parts.

  2. Clinical Particulars

4.1 Target species:

Dogs

4.2 Indications for use, specifying the target species:

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease in the dog.

The tablets also can be used in the management of post operative pain.

Contraindications:

Do not exceed the stated dose.

Do not use in cats.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.

Do not use in puppies less than 4 months.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Refer to section 4.7 and 4.8

4.4 Special Warnings for each target species:

See sections 4.3 and 4.5.

4.5 Special precautions for use:

Special precautions for use in animals:

Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion seek medical advice and show the package leaflet or the label to the physician. Wash hands after handling product.

4.6 Adverse reactions (frequency and seriousness):

Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

As with other NSAIDs there is a risk of rare renal or idosyncratic hepatic adverse events.

4.7 Use during pregnancy, lactation or lay:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose.  The safety of the veterinary medicinal product has not been established during pregnancy and lactation.  Do not use in pregnant or lactating bitches.  For breeding animals, do not use during reproduction period.

Interaction with other medicinal products and other forms of interaction:

Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects.  Do not use this veterinary medicinal product concurrently with or within 24 hours of other NSAIDs or concurrently with glucocorticoids.  

Concurrent administration of potentially nephrotoxic drugs should be avoided. Refer also to section 4.5.

Do not administer concurrently with anticoagulants.

Amounts to be administered and administration route:

For oral administration. The tablets are palatable and willingly consumed by most dogs when offered. 2 to 4 mg carprofen per kg bodyweight per day. An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose. Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4mg/kg/day for up to 5 days. Do not exceed the stated dose.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary:

No signs of toxicity were observed when dogs were administered the product at levels up to 6 mg/kg twice daily for 8 days (3 times the maximum recommended dose rate of 4 mg/kg/day) and 6 mg/kg once daily for a further 7 days (1.5 times the maximum recommended dose rate of 4 mg/kg/day). There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs, should be applied.

Severe adverse reactions may occur if large quantities are ingested. If you suspect that your dog has consumed tablets above the labelled dose, contact your veterinarian.

4.11 Withdrawal period:

Not applicable

  1. pharmacological properties

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids, proprionic acid derivatives, carprofen. ATC Vet Code: QM01AE91

5.1 Pharmacodynamic properties:

Carprofen is a member of the 2 –arylpropionic acid group of non steroidal anti-inflammatory drugs (NSAIDs) and possesses anti-inflammatory, analgesic and antipyretic activity.

Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. At therapeutic doses in the dog inhibition of the products of cyclo-oxygenase (prostaglandins and thromboxanes) or lipoxygenase (leukotrienes) has been absent or slight. The precise mode of action of carprofen is not clear.

5.2 Pharmacokinetic Particulars

After a single oral administration of 4 mg of carprofen per kg of bodyweight in dogs, the time to obtain a maximum plasmatic concentration of 31 g/ml is 2.5 hours.  The oral bioavailability is more than 90% of the total dose.  Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low.  Carprofen is excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate.  Carprofen undergoes an enantioselective enterohepatic cycle in dogs, with only the S(+) enantiomer being significantly recycled.  The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen.  The biliary clearance of S(+) carprofen seems to be subject to stereoselectively too as it is about three times higher than that of R(-) carprofen.    

Carprofen is mainly excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate, and 8-15% via urine.
  1. Pharmaceutical particulars

6.1 List of excipients:

Lactose Monohydrate
Sodium Laurilsulfate
Spray dried Pig liver powder EHT
Sucrose
Yeast extract (dried)
Ground Wheatgerm Starch Pregelatinised
Povidone K30
Microcrystalline Cellulose Guar Gum
Magnesium Stearate

6.2 Incompatibilities:

Not applicable

6.3 Shelf life:

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.

Shelf-life after first opening the immediate packaging: 24 hours. Any divided tablet portions remaining after 24 hours should be discarded.

6.4 Special precautions for storage:

Store in a dry place. Protect from light. Do not store above 25ºC Divided tablets should be stored in the blister pack.

6.5 Nature and composition of immediate packaging:

Aluminium-Aluminium packs of 10 tablets per strip in cartons containing 20, 100, 200, or 500 tablets. Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

    Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP Northern Ireland

  2. MARKETING AUTHORISATION NUMBER

    Vm 02000/4303

  3. DATE OF FIRST AUTHORISATION

    15 March 2011

  4. DATE OF REVISION OF THE TEXT

    May 2016

    Approved: 20 May 2016

50mg Flavour » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. Name of the veterinary medicinal product

    Carprieve 50 mg Flavoured Tablets for Dogs (UK, AT, BG, CY, CZ, EE, IE, LV, LT, RO, SK, SL) Norocarp 50mg Flavoured Tablets for Dogs (BE, EL, HU, IT, LU, NL. PT, ES) Norodyl Flavour 50mg Tablets for Dogs (DK) Carprieve 50 mg Chewable Tablets for Dogs (FI) Carprieve F 50mg Tablets for Dogs (FR) Carprieve 50mg Flavoured Tablets for Dogs (DE) Scanodyl 50mg Flavoured Tablets for Dogs (PL) Norocarp vet 50 mg Chewable Tablets for Dogs (SE)

  2. Qualitative and quantitative composition

    Each tablet contains:
    

Active Substance: Carprofen 50mg

Excipients:

For the full list of excipients see section 6.1
  1. Pharmaceutical form

    Tablet. Light brown, round, flat, bevel edged tablet The tablets can be divided into equal parts.

  2. Clinical Particulars

4.1 Target species:

Dogs

4.2 Indications for use, specifying the target species:

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease in the dog.

The tablets also can be used in the management of post operative pain.

Contraindications:

Do not exceed the stated dose.

Do not use in cats.  

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.

Do not use in puppies less than 4 months.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Refer to section 4.7 and 4.8

4.4 Special Warnings for each target species:

See sections 4.3 and 4.5.

 Special precautions for use:

Special precautions for use in animals:

Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion seek medical advice and show the package leaflet or the label to the physician. Wash hands after handling product.

4.6 Adverse reactions (frequency and seriousness):

Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

As with other NSAIDs there is a risk of rare renal or idosyncratic hepatic adverse events.

4.7 Use during pregnancy, lactation or lay:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose.  The safety of the veterinary medicinal product has not been established during pregnancy and lactation.  Do not use in pregnant or lactating bitches.  For breeding animals, do not use during reproduction period.

Interaction with other medicinal products and other forms of interaction:

Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects.  Do not use this veterinary medicinal product concurrently with or within 24 hours of other NSAIDs or concurrently with glucocorticoids.  

Concurrent administration of potentially nephrotoxic drugs should be avoided. Refer also to section 4.5.

Do not administer concurrently with anticoagulants.

Amounts to be administered and administration route:

For oral administration. The tablets are palatable and willingly consumed by most dogs when offered. 2 to 4 mg carprofen per kg bodyweight per day. An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose. Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4mg/kg/day for up to 5 days. Do not exceed the stated dose.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary:

No signs of toxicity were observed when dogs were administered the product at levels up to 6 mg/kg twice daily for 8 days (3 times the maximum recommended dose rate of 4 mg/kg/day) and 6 mg/kg once daily for a further 7 days (1.5 times the maximum recommended dose rate of 4 mg/kg/day). There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs, should be applied.

Severe adverse reactions may occur if large quantities are ingested. If you suspect that your dog has consumed tablets above the labelled dose, contact your veterinarian.

4.11 Withdrawal period:

Not applicable

  1. pharmacological properties

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids, proprionic acid derivatives, carprofen. ATC Vet Code: QM01AE91

5.1 Pharmacodynamic properties:

Carprofen is a member of the 2 –arylpropionic acid group of non steroidal anti-inflammatory drugs (NSAIDs) and possesses anti-inflammatory, analgesic and antipyretic activity.

Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. At therapeutic doses in the dog inhibition of the products of cyclo-oxygenase (prostaglandins and thromboxanes) or lipoxygenase (leukotrienes) has been absent or slight. The precise mode of action of carprofen is not clear.

5.2 Pharmacokinetic Particulars

After a single oral administration of 4 mg of carprofen per kg of bodyweight in dogs, the time to obtain a maximum plasmatic concentration of 31 g/ml is 2.5 hours.  The oral bioavailability is more than 90% of the total dose.  Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low.  Carprofen is excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate.  Carprofen undergoes an enantioselective enterohepatic cycle in dogs, with only the S(+) enantiomer being significantly recycled.  The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen.  The biliary clearance of S(+) carprofen seems to be subject to stereoselectively too as it is about three times higher than that of R(-) carprofen.    

Carprofen is mainly excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate, and 8-15% via urine.
  1. Pharmaceutical particulars

6.1 List of excipients:

Lactose Monohydrate
Sodium Laurilsulfate
Spray dried Pig liver powder EHT
Sucrose
Yeast extract (dried)
Ground Wheatgerm Starch Pregelatinised
Povidone K30
Microcrystalline Cellulose Guar Gum Magnesium Stearate

6.2 Incompatibilities:

Not applicable

6.3 Shelf life:

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.

Shelf-life after first opening the immediate packaging: 24 hours. Any divided tablet portions remaining after 24 hours should be discarded.

6.4 Special precautions for storage:

Store in a dry place. Protect from light. Do not store above 25ºC Divided tablets should be stored in the blister pack.

6.5 Nature and composition of immediate packaging:

Aluminium-Aluminium packs of 5 tablets per strip in cartons containing 20, 100, 200, or 500 tablets. Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

    Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP Northern Ireland

  2. MARKETING AUTHORISATION NUMBER

    Vm 02000/4304

  3. DATE OF FIRST AUTHORISATION

    15 March 2011

  4. DATE OF REVISION OF THE TEXT

    May 2016

    Approved: 20 May 2016

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (14)

Q & A

Below are some recent questions we've received regarding Carprieve, including answers from our team.

16 December 2013 at 10:04am

Alternative to Carprieve

Steffie Lewisham

I am looking to place an order with you but i wonder if you could advise me, at the moment he is on carprieve 50mg (one & half tablets a day) but after reading the possible side affects i am looking for an alternative and i am wondering if you know of something more kidney friendly and with less side affects,any advice would be much appreciated">carprieve 50mg (one & half tablets a day) but after reading the possible side affects i am looking for an alternative and i am wondering if you know of something more kidney friendly and with less side affects,any advice would be much appreciated

  • Website Content Developer

This is a bit like wanting an alternative to Nurofen if you have a headache. There are safer alternatives, but they are not as effective and the genuine risk of taking the original product is very low. Some people would rather have the headache than the pill, others take the pills happily (and usually are perfectly well).

There are a number of non-prescription products used to relieve stiffness and discomfort in the joints of older dogs. If this is the reason you were thinking of giving Carprieve then you could consider Seraquin or Yumove instead. They are very safe, with no recognised side effects, but they are not as potent or effective in most dogs. They do seem to be helpful for many individuals, but need to be used for a few weeks for the full benefit to develop.

I think that you need to judge how much your dog is in discomfort without the Carprieve, and balance a slight, potential risk against a genuine, probable benefit. The choice is yours. What do you think your dog would say if you could discuss it with him and ask him?